Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Creative Planning

Creative Planning decreased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 3.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,677 shares of the biotechnology company’s stock after selling 260 shares during the quarter. Creative Planning’s holdings in Sarepta Therapeutics were worth $959,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in SRPT. Riggs Asset Managment Co. Inc. lifted its holdings in shares of Sarepta Therapeutics by 125.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 125 shares in the last quarter. Innealta Capital LLC acquired a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at $31,000. New Covenant Trust Company N.A. acquired a new position in shares of Sarepta Therapeutics during the 1st quarter valued at $32,000. Nkcfo LLC acquired a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at $43,000. Finally, UMB Bank n.a. lifted its holdings in shares of Sarepta Therapeutics by 105.9% during the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 197 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Jefferies Financial Group assumed coverage on shares of Sarepta Therapeutics in a report on Monday, October 21st. They issued a “buy” rating and a $165.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $205.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 14th. William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Royal Bank of Canada reiterated an “outperform” rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 21st. Finally, Evercore ISI upgraded shares of Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and cut their price objective for the stock from $185.00 to $179.00 in a report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Sarepta Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $182.95.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $123.29 on Friday. The firm has a 50-day simple moving average of $127.42 and a 200 day simple moving average of $132.56. Sarepta Therapeutics, Inc. has a fifty-two week low of $75.69 and a fifty-two week high of $173.25. The company has a market cap of $11.76 billion, a PE ratio of 273.98 and a beta of 0.82. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.01 by $0.06. The company had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. Sarepta Therapeutics’s revenue was up 38.9% compared to the same quarter last year. During the same quarter last year, the business earned ($0.27) earnings per share. On average, sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post 1.48 EPS for the current year.

Insider Activity at Sarepta Therapeutics

In related news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Sarepta Therapeutics news, Director Michael Andrew Chambers purchased 37,038 shares of the business’s stock in a transaction dated Friday, August 16th. The shares were acquired at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the acquisition, the director now owns 284,034 shares of the company’s stock, valued at $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.